Samsung Biologics: IPO will support ambition to be top bio-CMO
Samsung Biologics says going public will help fulfil its ambition to become the world’s largest biologics contract manufacturing organisation (CMO).
Archives for April 28, 2016
AbbVie adds stem cell-based ADC in $5.8bn Stemcentrx acquisition
AbbVie has added the late-stage antibody-drug conjugate (ADC) Rova-T to its pipeline through the $5.8bn acquisition of Stemcentrx.
Biotrinity 2016
CRISPR-Cas9 gene editing tech could eliminate orphan diseases, entrepreneur
CRISPR-Cas9 technology has the potential to eliminate orphan diseases, according to a British life science entrepreneur and investor.